17P Using ex vivo organ culture technology to evaluate a T cell bispecific (TCB) CEACAM5 therapy. (December 2022) - Zundelevich, A.; Ibrahim, B.; Turovsky, L.; Aharon, S.; Bar, V.; Salpeter, S.; Neev, G.; Straussman, R.; Silva, I.; Li, S.; Herter, S.; Bacac, M.; et al.